Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Hypercalcaemia in alphacalcidol therapy

Postgraduate Medical Journal

|July 1, 1981

Summary

This summary is machine-generated.

Alphacalcidol treatment for hypoparathyroidism can cause severe hypercalcemia and potential kidney damage. Careful monitoring of plasma calcium levels is crucial during alphacalcidol therapy, especially for long-term management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prescribing a website.

Scottish medical journal·2005

Same author

Bone health in patients with fibromyalgia.

Rheumatology (Oxford, England)·2003

Same author

Peripheral bone mineral density in patients with distal radial fractures.

The Journal of bone and joint surgery. British volume·2003

Same author

Musculo-skeletal problems associated with pregnancy in women with osteogenesis imperfecta.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology·2003

Same author

Severe symptomatic osteoporosis in patients on androgen deprivation therapy for prostatic carcinoma.

Scandinavian journal of urology and nephrology·2002

Same author

Osteopenia has a differential diagnosis.

Scottish medical journal·2002

Same journal

Dapagliflozin-induced anaphylactic shock.

Postgraduate medical journal·2026

Same journal

Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials.

Postgraduate medical journal·2026

Same journal

Two cases of toxic epidermal necrolysis with severe ocular involvement treated with adjunctive tofacitinib.

Postgraduate medical journal·2026

Same journal

Diastolic dysfunction and diabetes: the DIADAD study-a retrospective cohort study from Liverpool.

Postgraduate medical journal·2026

Same journal

Care, cash, and proof: forensic accountability for war-related starvation.

Postgraduate medical journal·2026

Same journal

Response to traumatic injuries in polo players in England.

Postgraduate medical journal·2026

See all related articles

Area of Science:

Endocrinology
Nephrology
Pharmacology

Background:

Hypoparathyroidism management often involves vitamin D analogs.
Alphacalcidol (1 alpha-hydroxycholecalciferol) is used for its rapid action.
Potential risks associated with vitamin D analog therapy require careful consideration.

Purpose of the Study:

To report cases of severe hypercalcemia in hypoparathyroid patients treated with alphacalcidol.
To highlight the risk of adverse events, including renal damage, with alphacalcidol.
To compare the safety profile of alphacalcidol with calciferol.

Main Methods:

Case series describing three women with hypoparathyroidism.
Treatment involved alphacalcidol (1 alpha-hydroxycholecalciferol).

Related Experiment Videos

Clinical observation and monitoring of plasma calcium levels and renal function.

Main Results:

All three patients developed severe symptomatic hypercalcemia.
One patient experienced permanent renal damage.
Alphacalcidol demonstrated a rapid onset of action but increased risk of toxicity.

Conclusions:

Alphacalcidol necessitates frequent plasma calcium monitoring due to a higher risk of hypercalcemia.
Calciferol may be a safer alternative for long-term management of hypoparathyroidism.
Vigilance is essential when prescribing alphacalcidol to prevent serious complications.